Skip to content

HOME
PROJECT
TEAM
- Meet our Early- & Mid-Career Researchers
- Meet our Partners
  RCSI (The Royal College of Surgeons in Ireland – University of Medicine and Health Sciences)
  Institut du Cerveau – Paris Brain Institute (ICM)
  German Center for Neurodegenerative Diseases (DZNE)
  University College London (UCL)
  Radboud University Nijmegen Medical Centre (RUMC)
  Centre National de la Recherche Scientifique (CNRS)
  GeneXplain GmbH (geneXplain)
  Mimetas
  Pintail Limited (PT)
  Teva Pharmaceutical Industries Ltd. (TEVA)
  Lundbeck
  UCB S.A. (UCB)
  Parkinson’s UK
GENERAL PUBLIC
- Informational videos
- Publication Summaries
MEDIA
NEWS
ResearchGate

3_Daniele_Bano_DZNE

pdmq_admin2021-03-11T11:39:47+00:00February 6th, 2019|

Search for:

PROJECT FACTS

Grant agreement number 821522
IMI2 JU contribution €4,617,933.75
Duration 36 months
Starting date 1 February 2019

#pdmitoquant on Twitter

; Innovative Health Initiative @IHIEurope ·

14 Mar 2023 1635659631115501571

IMI projects like #PDMitoQUANT, ADAPTED, IMPRIND and PHAGO addressed the molecular underpinnings of #Parkinson's and #Alzheimer’s disease, translating their findings into new tools, assays & platforms.
More on our impacts: http://bit.ly/3vVJjwo
#BAW2023 #BrainAwarenessWeek

Twitter feed video.

; Pintail Limited @PintailLimited ·

9 Sep 2022 1568212559106396166

Neuronal hyperactivity–induced oxidant stress promotes in vivo α-synuclein brain spreading #PDMitoQUANT @IHIEurope @IMI2_NEURONET @DZNE_en https://www.science.org/doi/10.1126/sciadv.abn0356#.YxsvHk1CZ0k.twitter

FUNDING ACKNOWLEDGEMENT

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821522. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Parkinson’s UK.

The material presented and views expressed here reflect the author’s view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.

Page load link

Go to Top